NASDAQ:PTGXProtagonist Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Protagonist Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $15.84 -0.16 (-1.00 %) (As of 05/26/2020 04:00 PM ET) Add Compare Share Today's Range$15.23Now: $15.84▼$16.5350-Day Range$6.19MA: $10.06▼$17.0552-Week Range$4.47Now: $15.84▼$17.33Volume437,400 shsAverage Volume642,501 shsMarket Capitalization$434.57 millionP/E RatioN/ADividend YieldN/ABeta0.8 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops peptide-based product candidates to address unmet medical needs in hematology and gastroenterology. The company is developing PTG-300, an injectable hepcidin mimetic that is in Phase II clinical trial for the treatment of patients with beta-thalassemia by targeting the chronic anemia; PTG-200, an antagonist peptide product candidate, which has completed Phase I clinical trial to treat inflammatory bowel disease (IBD); and PN-943, an oral, alpha-4-beta-7 specific integrin antagonist that is in Phase I clinical trial for treating IBD. It is also involved in researching oral and injectable peptide-based product candidates for a range of conditions, including gastrointestinal diseases. The company was founded in 2006 and is headquartered in Newark, California.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingProtagonist Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $30.60, Protagonist Therapeutics has a potential upside of 93.2% from its current price of $15.84.Amount of Analyst CoverageProtagonist Therapeutics has only been the subject of 4 research reports in the past 90 days. Previous Next 2.2 Community Rank Outperform VotesProtagonist Therapeutics has received 212 “outperform” votes. (Add your “outperform” vote.)Underperform VotesProtagonist Therapeutics has received 278 “underperform” votes. (Add your “underperform” vote.)Community SentimentProtagonist Therapeutics has received 56.73% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Protagonist Therapeutics and other stocks. Vote “Outperform” if you believe PTGX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PTGX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldProtagonist Therapeutics does not currently pay a dividend.Dividend GrowthProtagonist Therapeutics does not have a long track record of dividend growth. Previous Next 4.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Protagonist Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $80,400.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 14.20% of the stock of Protagonist Therapeutics is held by insiders.Percentage Held by Institutions85.62% of the stock of Protagonist Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Protagonist Therapeutics are expected to grow in the coming year, from ($2.55) to ($1.71) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Protagonist Therapeutics is -5.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Protagonist Therapeutics is -5.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioProtagonist Therapeutics has a P/B Ratio of 5.39. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™2.07 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PTGX Previous Symbol CUSIPN/A CIK1377121 Webwww.protagonist-inc.com Phone510-474-0170Debt Debt-to-Equity Ratio0.25 Current Ratio3.46 Quick Ratio3.46Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$230,000.00 Price / Sales1,889.44 Cash FlowN/A Price / Cash FlowN/A Book Value$2.94 per share Price / Book5.39Profitability EPS (Most Recent Fiscal Year)($2.98) Net Income$-77,190,000.00 Net MarginsN/A Return on Equity-103.21% Return on Assets-56.14%Miscellaneous Employees64 Outstanding Shares27,435,000Market Cap$434.57 million Next Earnings Date8/5/2020 (Estimated) OptionableNot Optionable NASDAQ:PTGX Rates by TradingView Receive PTGX News and Ratings via Email Sign-up to receive the latest news and ratings for PTGX and its competitors with MarketBeat's FREE daily newsletter. Protagonist Therapeutics (NASDAQ:PTGX) Frequently Asked Questions How has Protagonist Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Protagonist Therapeutics' stock was trading at $7.16 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, PTGX shares have increased by 121.2% and is now trading at $15.84. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Protagonist Therapeutics? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Protagonist Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Protagonist Therapeutics. When is Protagonist Therapeutics' next earnings date? Protagonist Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Protagonist Therapeutics. How were Protagonist Therapeutics' earnings last quarter? Protagonist Therapeutics Inc (NASDAQ:PTGX) announced its quarterly earnings results on Thursday, May, 7th. The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.69) by $0.03. The business had revenue of $3.65 million for the quarter, compared to the consensus estimate of $3.60 million. View Protagonist Therapeutics' earnings history. What price target have analysts set for PTGX? 5 analysts have issued 1 year price targets for Protagonist Therapeutics' stock. Their forecasts range from $28.00 to $33.00. On average, they expect Protagonist Therapeutics' stock price to reach $30.60 in the next twelve months. This suggests a possible upside of 93.2% from the stock's current price. View analysts' price targets for Protagonist Therapeutics. Has Protagonist Therapeutics been receiving favorable news coverage? Media coverage about PTGX stock has been trending extremely negative recently, InfoTrie reports. The research group rates the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Protagonist Therapeutics earned a news impact score of -4.0 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the immediate future. View the latest news aboutProtagonist Therapeutics. Are investors shorting Protagonist Therapeutics? Protagonist Therapeutics saw a drop in short interest in May. As of May 15th, there was short interest totaling 1,120,000 shares, a drop of 13.8% from the April 30th total of 1,300,000 shares. Based on an average daily volume of 760,700 shares, the days-to-cover ratio is presently 1.5 days. Currently, 5.4% of the shares of the stock are short sold. View Protagonist Therapeutics' Current Options Chain. Who are some of Protagonist Therapeutics' key competitors? Some companies that are related to Protagonist Therapeutics include Eidos Therapeutics (EIDX), Theravance Biopharma (TBPH), Arvinas (ARVN), Dicerna Pharmaceuticals (DRNA), Opko Health (OPK), Heron Therapeutics (HRTX), Arcus Biosciences (RCUS), Zymeworks (ZYME), Akebia Therapeutics (AKBA), CytoDyn (CYDY), Constellation Pharmaceuticals (CNST), Y-mAbs Therapeutics (YMAB), BELLUS Health (BLUSF), Karyopharm Therapeutics (KPTI) and Intra-Cellular Therapies (ITCI). View all competitors. What other stocks do shareholders of Protagonist Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Protagonist Therapeutics investors own include Viking Therapeutics (VKTX), Agile Therapeutics (AGRX), TG Therapeutics (TGTX), ImmunoGen (IMGN), Novavax (NVAX), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Abeona Therapeutics (ABEO) and Energy Transfer LP Unit (ET). Who are Protagonist Therapeutics' key executives? Protagonist Therapeutics' management team includes the following people: Dr. Dinesh V. Patel, CEO, Pres, Interim Principal Financial Officer, Interim PAO, Sec. & Director (Age 62)Dr. Richard S. Shames, Chief Medical Officer (Age 59)Dr. David Y. Liu, Chief Scientific Officer and Head of R&D (Age 69)Dr. Mark Smythe, VP of Technology (Age 54)Dr. Samuel R. Saks, Chief Devel. Officer (Age 64) When did Protagonist Therapeutics IPO? (PTGX) raised $70 million in an initial public offering (IPO) on Thursday, August 11th 2016. The company issued 5,800,000 shares at $11.00-$13.00 per share. Leerink Partners, Barclays and BMO Capital Markets served as the underwriters for the IPO. What is Protagonist Therapeutics' stock symbol? Protagonist Therapeutics trades on the NASDAQ under the ticker symbol "PTGX." Who are Protagonist Therapeutics' major shareholders? Protagonist Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (5.68%), JPMorgan Chase & Co. (3.22%), Sphera Funds Management LTD. (1.92%), State Street Corp (1.16%), Geode Capital Management LLC (1.07%) and Ghost Tree Capital LLC (0.83%). Company insiders that own Protagonist Therapeutics stock include Bryan Giraudo, David Y Liu, Dinesh V Ph D Patel, Donald A Kalkofen, Harold E Selick, Richard S Shames and Suneel Gupta. View institutional ownership trends for Protagonist Therapeutics. Which institutional investors are selling Protagonist Therapeutics stock? PTGX stock was sold by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Sphera Funds Management LTD., Nuveen Asset Management LLC, Two Sigma Advisers LP, Two Sigma Investments LP, Squarepoint Ops LLC, WINTON GROUP Ltd, and Ghost Tree Capital LLC. Company insiders that have sold Protagonist Therapeutics company stock in the last year include David Y Liu, and Dinesh V Ph D Patel. View insider buying and selling activity for Protagonist Therapeutics. Which institutional investors are buying Protagonist Therapeutics stock? PTGX stock was purchased by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., VR Adviser LLC, Invesco Ltd., Ikarian Capital LLC, Russell Investments Group Ltd., UBS Group AG, Los Angeles Capital Management & Equity Research Inc., and Geode Capital Management LLC. Company insiders that have bought Protagonist Therapeutics stock in the last two years include Bryan Giraudo, Donald A Kalkofen, Harold E Selick, and Suneel Gupta. View insider buying and selling activity for Protagonist Therapeutics. How do I buy shares of Protagonist Therapeutics? Shares of PTGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Protagonist Therapeutics' stock price today? One share of PTGX stock can currently be purchased for approximately $15.84. How big of a company is Protagonist Therapeutics? Protagonist Therapeutics has a market capitalization of $434.57 million and generates $230,000.00 in revenue each year. The company earns $-77,190,000.00 in net income (profit) each year or ($2.98) on an earnings per share basis. Protagonist Therapeutics employs 64 workers across the globe. What is Protagonist Therapeutics' official website? The official website for Protagonist Therapeutics is www.protagonist-inc.com. How can I contact Protagonist Therapeutics? Protagonist Therapeutics' mailing address is 7707 GATEWAY BOULEVARD SUITE 140, NEWARK CA, 94560. The company can be reached via phone at 510-474-0170 or via email at [email protected] This page was last updated on 5/27/2020 by MarketBeat.com Staff
